רופילק 300

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

ANTI-D IMMUNOGLOBULINS

Disponible depuis:

CSL BEHRING LTD., ISRAEL

Code ATC:

J06BB01

forme pharmaceutique:

תמיסה להזרקה

Composition:

ANTI-D IMMUNOGLOBULINS 150 MCG/ML

Mode d'administration:

תוך-שרירי, תוך-ורידי

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

CSL BEHRING AG, SWITZERLAND

Groupe thérapeutique:

ANTI-D (RH) IMMUNOGLOBULIN

Domaine thérapeutique:

ANTI-D (RH) IMMUNOGLOBULIN

indications thérapeutiques:

Prophylaxis of Rh (D) immunisation in Rh (D)-negative women: Anti-D immune globulin is administered for the prevention of Rh (D) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. Treatment is not necessary when it is assured that the child or the father are Rh (D)- negative. Criteria for a rhesus-incompatible pregnancy and the administration of anti-D immune globulin are : a) the mother is Rh (D) -negative b) the child is either Rh (D)-positive Rh (D)weak - positive or its rhesus type is not known. Routine antepartum prophylaxis : To prevent Rh (D) immunisation due to spontaneous fetomaternal haemorrhage (FMH) during the last trimester of pregnancy. Postpartum prophylaxis To prevent Rh (D) immunisation of the Rh (D)-negative mother following delivery of a Rh (D)-positive child. Complications of pregnancy: Interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Date de l'autorisation:

2023-02-28